Bristol-Myers Squibb (BMY), Turning Point Therapeutics (TPRX) Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition Aug 16, 2022 06:59AM
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Th Aug 16, 2022 06:59AM
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022 Jul 27, 2022 06:59AM
Bristol-Myers Squibb (BMY) Announces Extension of Turning Point (TPTX) Tender Offer Jul 19, 2022 06:59AM
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer Jul 19, 2022 06:59AM


Jun 3, 2022 06:59AM Bristol-Myers Squibb (BMY) to Acquire Turning Point Therapeutics (TPTX) for $76 Per Share
Jun 3, 2022 06:59AM Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
Apr 28, 2022 07:31AM Turning Point (TPTX) and Zai Lab (ZLAB) Report Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Apr 28, 2022 07:30AM Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Apr 28, 2022 07:30AM Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Apr 28, 2022 07:30AM Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Oct 13, 2021 04:01PM Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Ca
Oct 4, 2021 09:10AM Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Jan 11, 2021 06:45AM Turning Point and Zai Lab Broaden Collaboration
Jan 11, 2021 06:45AM Turning Point and Zai Lab Broaden Collaboration
Jan 11, 2021 04:30AM Turning Point and Zai Lab Broaden Collaboration
Jan 11, 2021 04:30AM Turning Point and Zai Lab Broaden Collaboration
Jul 7, 2020 07:35AM Turning Point Therapeutics Inc. (TPTX), Zai Lab (ZLAB) Announce Exclusive License Agreement for Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
Jul 7, 2020 07:30AM Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China